The pharmaceutical industry in most ASEAN markets is growing and dynamic, albeit at variant
rates. This growth is driven by several factors including the emergence of more efficient health
systems that are expanding access for consumers. Both innovative and generic pharmaceutical
sectors are benefiting from this growth. However, expansion of healthcare access has also
created financial and budgetary strains. The EU pharmaceutical sector stands ready to be a collaborative partner. Finally, and most importantly, the EU bilateral FTA’s with certain ASEAN markets have the potential to be the most significant driver for opening the markets and benefiting EU and ASEAN companies.
This positioning paper is not available for public.
Please contact [email protected] for more information.
